◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › TARA

Protara Therapeutics, Inc. (TARA) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-10

Protara Therapeutics, Inc. (TARA) operates in the Biotechnology industry and is headquartered in New York, United States with about 46 employees. Its market capitalization is roughly $236 million. In the fiscal year ended 2025-12-31, TARA reported $0M in revenue and ($57M) in net income.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.

Interactive charts & full statements →

TARA Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($64M)($49M)($44M)($38M)
Net Income($57M)($45M)($40M)($66M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TARA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($20M)($19M)($15M)($17M)($14M)
Net Income($18M)($17M)($13M)($15M)($12M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TARA Free Cash Flow History

TARA Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$210M$182M$79M$113M
Total Liabilities$13M$14M$11M$11M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TARA viewer.

Other Companies in Biotechnology

← TAP.AAll stocksTARS →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.